Emerging importance of ALK in neuroblastoma

Seminars in Cancer Biology

Volumn 21, Issue 4, 2011, Pages 267-275

  Azarova, Anna M ^a   Gautam, Gargi ^a,b   George, Rani E ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ALK; Combination treatment; Crizotinib; Drug resistance; Neuroblastoma; Point mutations; Small molecule inhibitors; Targeted therapy; Tyrosine kinase receptor

Indexed keywords

3,5 DIAMINO 1,2,4 TRIAZOLE BENZYLUREA; 5 CHLORO 2,4 DIAMINOPHENYLPYRIMIDINE; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; ASP 3026; CARBAZOLE DERIVATIVE; CEP 28122; CH 5424802; CRIZOTINIB; CRL 151104A; GELDANAMYCIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; INSULIN RECEPTOR; LIPOSOME; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; RETASPIMYCIN; SMALL INTERFERING RNA; TAE 684; TANESPIMYCIN; UNCLASSIFIED DRUG;

BETA SHEET; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CATALYSIS; COPY NUMBER VARIATION; CRYSTAL STRUCTURE; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SPECIFICITY; GAIN OF FUNCTION MUTATION; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LUNG CANCER; NEUROBLASTOMA; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; POINT MUTATION; PROGNOSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SOMATIC MUTATION;

ANIMALS; GENES, MYC; HUMANS; NEUROBLASTOMA; POINT MUTATION; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 80655124524     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2011.09.005     Document Type: Review

References (79)

1. Morris S.W., Kirstein M.N., Valentine M.B., Dittmer K.G., Shapiro D.N., Saltman D.L., et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994, 263:1281-1284.
2. Chiarle R., Voena C., Ambrogio C., Piva R., Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008, 8:11-23.
3. Chen Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M., et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008, 455:971-974.
4. George R.E., Sanda T., Hanna M., Frohling S., Luther W., Zhang J., et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008, 455:975-978.
5. Janoueix-Lerosey I., Lequin D., Brugieres L., Ribeiro A., de Pontual L., Combaret V., et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008, 455:967-970.
6. Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A., Attiyeh E.F., et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008, 455:930-935.
7. Webb T.R., Slavish J., George R.E., Look A.T., Xue L., Jiang Q., et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther 2009, 9:331-356.
8. Mathew P., Morris S.W., Kane J.R., Shurtleff S.A., Pasquini M., Jenkins N.A., et al. Localization of the murine homolog of the anaplastic lymphoma kinase (AlK) gene on mouse chromosome 17. Cytogenet Cell Genet 1995, 70:143-144.
9. Palmer R.H., Vernersson E., Grabbe C., Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 2009, 420:345-361.
10. Iwahara T., Fujimoto J., Wen D., Cupples R., Bucay N., Arakawa T., et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997, 14:439-449.
11. Morris S.W., Naeve C., Mathew P., James P.L., Kirstein M.N., Cui X., et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 1997, 14:2175-2188.
12. Pulford K., Lamant L., Morris S.W., Butler L.H., Wood K.M., Stroud D., et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 1997, 89:1394-1404.
13. Degoutin J., Brunet-de Carvalho N., Cifuentes-Diaz C., Vigny M. ALK (Anaplastic Lymphoma Kinase) expression in DRG neurons and its involvement in neuron-Schwann cells interaction. Eur J Neurosci 2009, 29:275-286.
14. Li R., Morris S.W. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev 2008, 28:372-412.
15. Stoica G.E., Kuo A., Powers C., Bowden E.T., Sale E.B., Riegel A.T., et al. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem 2002, 277:35990-35998.
16. Powers C., Aigner A., Stoica G.E., McDonnell K., Wellstein A. Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J Biol Chem 2002, 277:14153-14158.
17. Stoica G.E., Kuo A., Aigner A., Sunitha I., Souttou B., Malerczyk C., et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem 2001, 276:16772-16779.
18. Hubbard S.R., Wei L., Ellis L., Hendrickson W.A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 1994, 372:746-754.
19. Munshi S., Kornienko M., Hall D.L., Reid J.C., Waxman L., Stirdivant S.M., et al. Crystal structure of the Apo, unactivated insulin-like growth factor-1 receptor kinase. Implication for inhibitor specificity. J Biol Chem 2002, 277:38797-38802.
20. Tartari C.J., Gunby R.H., Coluccia A.M., Sottocornola R., Cimbro B., Scapozza L., et al. Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase. J Biol Chem 2008, 283:3743-3750.
21. Lee C.C., Jia Y., Li N., Sun X., Ng K., Ambing E., et al. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem J 2010, 430:425-437.
22. Bossi R.T., Saccardo M.B., Ardini E., Menichincheri M., Rusconi L., Magnaghi P., et al. Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry 2010, 49:6813-6825.
23. Vernersson E., Khoo N.K., Henriksson M.L., Roos G., Palmer R.H., Hallberg B. Characterization of the expression of the ALK receptor tyrosine kinase in mice. Gene Expr Patterns 2006, 6:448-461.
24. Hurley S.P., Clary D.O., Copie V., Lefcort F. Anaplastic lymphoma kinase is dynamically expressed on subsets of motor neurons and in the peripheral nervous system. J Comp Neurol 2006, 495:202-212.
25. Bilsland J.G., Wheeldon A., Mead A., Znamenskiy P., Almond S., Waters K.A., et al. Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications. Neuropsychopharmacology 2008, 33:685-700.
26. Loren C.E., Englund C., Grabbe C., Hallberg B., Hunter T., Palmer R.H. A crucial role for the anaplastic lymphoma kinase receptor tyrosine kinase in gut development in Drosophila melanogaster. EMBO Rep 2003, 4:781-786.
27. Loren C.E., Scully A., Grabbe C., Edeen P.T., Thomas J., McKeown M., et al. Identification and characterization of DAlk: a novel Drosophila melanogaster RTK which drives ERK activation in vivo. Genes Cells 2001, 6:531-544.
28. Souttou B., Carvalho N.B., Raulais D., Vigny M. Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway. J Biol Chem 2001, 276:9526-9531.
29. Motegi A., Fujimoto J., Kotani M., Sakuraba H., Yamamoto T. ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth. J Cell Sci 2004, 117:3319-3329.
30. Piccinini G., Bacchiocchi R., Serresi M., Vivani C., Rossetti S., Gennaretti C., et al. A ligand-inducible epidermal growth factor receptor/anaplastic lymphoma kinase chimera promotes mitogenesis and transforming properties in 3T3 cells. J Biol Chem 2002, 277:22231-22239.
31. Perez-Pinera P., Zhang W., Chang Y., Vega J.A., Deuel T.F. Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation. J Biol Chem 2007, 282:28683-28690.
32. Miyake I., Hakomori Y., Shinohara A., Gamou T., Saito M., Iwamatsu A., et al. Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene 2002, 21:5823-5834.
33. Gouzi J.Y., Moog-Lutz C., Vigny M., Brunet-de Carvalho N. Role of the subcellular localization of ALK tyrosine kinase domain in neuronal differentiation of PC12 cells. J Cell Sci 2005, 118:5811-5823.
34. Dirks W.G., Fahnrich S., Lis Y., Becker E., MacLeod R.A., Drexler H.G. Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. Int J Cancer 2002, 100:49-56.
35. Englund C., Loren C.E., Grabbe C., Varshney G.K., Deleuil F., Hallberg B., et al. Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion. Nature 2003, 425:512-516.
36. Varshney G.K., Palmer R.H. The bHLH transcription factor Hand is regulated by Alk in the Drosophila embryonic gut. Biochem Biophys Res Commun 2006, 351:839-846.
37. Lee H.H., Norris A., Weiss J.B., Frasch M. Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers. Nature 2003, 425:507-512.
38. Mourali J., Benard A., Lourenco F.C., Monnet C., Greenland C., Moog-Lutz C., et al. Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage. Mol Cell Biol 2006, 26:6209-6222.
39. Muramatsu T. Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem 2002, 132:359-371.
40. Caren H., Abel F., Kogner P., Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 2008, 416:153-159.
41. Longo L., Borghini S., Schena F., Parodi S., Albino D., Bachetti T., et al. PHOX2A and PHOX2B genes are highly co-expressed in human neuroblastoma. Int J Oncol 2008, 33:985-991.
42. Wood A.C.L.M., Haglund E.A., Attiyeh E.F., Pawel B., Courtright J., Plegaria J., et al. Inhibition of ALK mutated neuroblastomas by the selective inhibitor PF-02341066. J Clin Oncol 2009, 27:15s. (suppl; abstr 10008b) 2009.
43. De Brouwer S., De Preter K., Kumps C., Zabrocki P., Porcu M., Westerhout E.M., et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 2011, 16:4353-4362.
44. Mazot P., Cazes A., Boutterin M.C., Figueiredo A., Raynal V., Combaret V., et al. The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking. Oncogene 2011, 30:2017-2025.
45. Weiser D L.M., Rappaport E., Carpenter E., Attiyeh E.F., Diskin S., London W.B., et al. Stratification of patients with neuroblastoma for targeted ALK inhibitor therapy. J Clin Oncol 2011, 29.
46. Schulte J.H., Bachmann H.S., Brockmeyer B., Depreter K., Oberthur A., Ackermann S., et al. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Clin Cancer Res 2011, 17:5082-5092.
47. George R L.W., Ahmad Z., Cullis E., Webber H., Rodig S., Pearson A., et al. The ALK-F1174L mutation accelerates MYCN-driven tumorigenesis in a murine transgenic neuroblastoma model [abstract]. Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 April 2-6; Orlando, Florida 2011, AACR, Philadelphia (PA), [Abstract nr 4757].
48. Zhu S L.J., Shin J., Perez-Atayde A., Kutok J., Rodig S., Neuberg D., et al. Activated ALK accelerates the onset of neuroblastoma in MYCN-transgenic zebrafish [abstract]. Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 April 2-6; Orlando, Florida 2011, AACR, Philadelphia (PA), [Abstract nr 4296].
49. Martinsson T., Eriksson T., Abrahamsson J., Caren H., Hansson M., Kogner P., et al. Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy. Cancer Res 2011, 71:98-105.
50. Sasaki T., Okuda K., Zheng W., Butrynski J., Capelletti M., Wang L., et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 2010, 70:10038-10043.
51. George R.E., Attiyeh E.F., Li S., Moreau L.A., Neuberg D., Li C., et al. Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS ONE 2007, 2:e255.
52. Passoni L., Longo L., Collini P., Coluccia A.M., Bozzi F., Podda M., et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res 2009, 69:7338-7346.
53. Lamant L., Pulford K., Bischof D., Morris S.W., Mason D.Y., Delsol G., et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 2000, 156:1711-1721.
54. Osajima-Hakomori Y., Miyake I., Ohira M., Nakagawara A., Nakagawa A., Sakai R. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol 2005, 167:213-222.
55. Schulte J.H., Bachmann H.S., Brockmeyer B., De Preter K., Oberthuer A., Ackermann S., et al. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Clin Cancer Res 2011, 17:5082-5092.
56. Zou H.Y., Li Q., Lee J.H., Arango M.E., McDonnell S.R., Yamazaki S., et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007, 67:4408-4417.
57. Timofeevski S.L., McTigue M.A., Ryan K., Cui J., Zou H.Y., Zhu J.X., et al. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry 2009, 48:5339-5349.
58. Christensen J.G., Zou H.Y., Arango M.E., Li Q., Lee J.H., McDonnell S.R., et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007, 6:3314-3322.
59. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
60. Rodig S.J., Shapiro G.I. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs 2010, 11:1477-1490.
61. Galkin A.V., Melnick J.S., Kim S., Hood T.L., Li N., Li L., et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci USA 2007, 104:270-275.
62. McDermott U., Iafrate A.J., Gray N.S., Shioda T., Classon M., Maheswaran S., et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008, 68:3389-3395.
63. Sakamoto H., Tsukaguchi T., Hiroshima S., Kodama T., Kobayashi T., Fukami T.A., et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011, 19:679-690.
64. Kuromitsu S., Mori M., Shimada I., Kondoh Y., Shindoh N., Soga T., et al. Anti-tumor activity of ASP3026-a novel and selective ALK inhibitor [abstract]. Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research 2011, [Abstract nr 2821].
65. Cheng M., Quail M.R., Gingrich D.E., Ott G.R., Lu L., Wan W., et al. Identification and preclinical characterization of CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase, in lymphoma and non-small cell lung cancer models [abstract]. Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research 2011, AACR, Orlando, Florida, Philadelphia (PA), [Abstract nr 3574].
66. Choi Y.L., Soda M., Yamashita Y., Ueno T., Takashima J., Nakajima T., et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010, 363:1734-1739.
67. Deng X., Wang J., Zhang J., Sim T., Kim N.D., Sasaki T., et al. Discovery of 3,5-diamino-1,2,4-triazole ureas as potent anaplastic lymphoma kinase inhibitors. ACS Med Chem Lett 2011, 2:379-384.
68. Stoffel A. Targeted therapies for solid tumors: current status and future perspectives. BioDrugs 2010, 24:303-316.
69. Martinelli E., Troiani T., Morgillo F., Rodolico G., Vitagliano D., Morelli M.P., et al. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. Clin Cancer Res 2010, 16:4990-5001.
70. Carpenter E H.E., Chow A., Christensen J., Maris J., Mosse Y. Mechanisms of resistance to small molecule inhibition of anaplastic lymphoma kinase in human neuroblastoma [abstract]. Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, Florida 2011, AACR, Philadelphia (PA), [Abstract nr 742].
71. Di Paolo D., Brignole C., Pastorino F., Carosio R., Zorzoli A., Rossi M., et al. Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK. Mol Ther 2011.
72. Bonvini P., Gastaldi T., Falini B., Rosolen A. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. Cancer Res 2002, 62:1559-1566.
73. Bonvini P., Dalla Rosa H., Vignes N., Rosolen A. Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein. Cancer Res 2004, 64:3256-3264.
74. Sequist L.V., Gettinger S., Senzer N.N., Martins R.G., Janne P.A., Lilenbaum R., et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010, 28:4953-4960.
75. Chen Z., Sasaki T., Tan X., Carretero J., Shimamura T., Li D., et al. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res 2010, 70:9827-9836.
76. Normant E., Paez G., West K.A., Lim A.R., Slocum K.L., Tunkey C., et al. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene 2011.
77. Engelman J.A., Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 2008, 18:73-79.
78. McDermott U., Pusapati R.V., Christensen J.G., Gray N.S., Settleman J. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res 2010, 70:1625-1634.
79. Carpenter El H.E., Chow A.K., Christensen J.G., Maris J.M., Mosse Y.P. Mechanisms of resistance to small molecule inhibition of anaplastic lymphoma kinase in human neuroblastoma. AACR Annual Meeting Proceedings 2011, [Abstract #742].